The Motley Fool
07 Jun 2026, 11:57 UTC · 19w ago
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Impact · against what's priced in
Aurinia Pharmaceuticals is showing strong commercial momentum and clinical validation for Lupkynis, supported by significant insider buying. The combination of 24% revenue growth, rising profitability, and long-term phase 3 data suggesting high efficacy provides a positive catalyst for the stock.
- AUPH+0.70
No priced-in read yet
- In context
The company reported a 48% YoY increase in annualized net income to $137.6 million and annualized sales of $310 million. Furthermore, long-term phase 3 data showing a reduction in kidney-related events or death by more than half and a 78% decrease in kidney damage signals provide a strong clinical basis for further sales growth.
